UBS Group
ELOX

UBS Group’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

UBS Group’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-291
Closed -$1.4K – 10576
2023
Q3 		$1.4K Buy
+291
New +$1.63K ﹤0.01% 7953
2023
Q2 		– Sell
-469
Closed -$1.18K – 10419
2023
Q1 		$1.18K Buy
469
+346
+281% +$1.25K ﹤0.01% 8790
2022
Q4 		$224 Buy
+123
New +$593 ﹤0.01% 10300
2022
Q2 		– Sell
-546
Closed -$12K – 11522
2022
Q1 		$12K Buy
+546
New +$10.7K ﹤0.01% 8259
2021
Q3 		– Sell
-291
Closed -$23K – 10474
2021
Q2 		$23K Buy
291
+152
+109% +$12.7K ﹤0.01% 7209
2021
Q1 		$18K Sell
139
-10
-7% -$1.53K ﹤0.01% 7494
2020
Q4 		$24K Buy
+149
New +$18.2K ﹤0.01% 6822
2020
Q3 		– Sell
-190
Closed -$23K – 8608
2020
Q2 		$23K Sell
190
-176
-48% -$19.9K ﹤0.01% 6479
2020
Q1 		$29K Sell
366
-458
-56% -$74.6K ﹤0.01% 6251
2019
Q4 		$243K Buy
824
+481
+140% +$96.9K ﹤0.01% 5460
2019
Q3 		$62K Buy
+343
New +$97.6K ﹤0.01% 6070
2019
Q1 		– Sell
-32
Closed -$15K – 8343
2018
Q4 		$15K Sell
32
-124
-79% -$68.4K ﹤0.01% 7004
2018
Q3 		$106K Buy
156
+93
+148% +$59.5K ﹤0.01% 5558
2018
Q2 		$43K Buy
+63
New +$40.8K ﹤0.01% 6111

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ELOX Position: Q4 2023 in Review

UBS Group sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2023, closing a stake of 291 shares — an estimated $1.4K sold.

UBS Group first reported a position in ELOX in Q2 2018 and held it in 14 quarters. The position peaked at $243K in Q4 2019. 4 funds tracked by Wall St. Rank hold ELOX as of Q4 2023.

  • UBS Group reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 291 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $1.4K.
  • UBS Group first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 14 quarters.
  • UBS Group's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $243K in Q4 2019.
  • 4 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.